Cephacetrile
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-00754 |
| CAS | 10206-21-0 |
| Molecular Weight | 339.32 |
| Molecular Formula | C13H13N3O6S |
| Purity | 95% |
Online Inquiry
Description
It is produced by the strain of Semisynthetic first generation cephalosporin for injection. Its sodium salt is used in preparations. It has the first-generation cephalosporin commonness. It is characterized by the excretion of more than 90% of the dose in the urine within 24 hours, so it is especially suitable for urinary tract infection caused by sensitive bacteria.
Specification
| Related CAS | 23239-41-0 (sodium salt) |
| Synonyms | C 36278 Ba; C-36278-Ba; C36278Ba; Cephacetrile Sodium; Sodium, Cephacetrile; Celospor; Cefacetrilum; Cefacetrilo; Cefacetrile; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester) |
| Storage | −20 °C under inert atmosphere |
| IUPAC Name | (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Canonical SMILES | CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CC#N)SC1)C(=O)O |
| InChI | InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1 |
| InChI Key | RRYMAQUWDLIUPV-BXKDBHETSA-N |
Properties
| Appearance | Needle Crystal |
| Boiling Point | 757.5±60.0 °C at 760 mmHg |
| Melting Point | 168-170 °C(dec.) |
| Density | 1.59±0.1 g/cm3 |
| Solubility | Soluble in Sodium Bicarbonate; Slightly soluble in DMF, DMSO, Methanol |
Reference Reading
1.ACOG Committee Opinion No. 645 Summary: Dual Therapy for Gonococcal Infections.
Committee on Gynecologic Practice. Obstet Gynecol. 2015 Nov;126(5):1126. doi: 10.1097/AOG.0000000000001144.
Gonorrhea is the second most commonly reported bacterial sexually transmitted disease in the United States, with an estimated 820,000 new Neisseria gonorrhoeae infections occurring each year. Antimicrobial resistance limits treatment success, heightens the risk of complications, and may facilitate the transmission of sexually transmitted infections. Neisseria gonorrhoeae has developed resistance to the sulfonamides, the tetracyclines, and penicillin. Dual therapy with ceftriaxone and azithromycin remains the only recommended first-line regimen for the treatment of gonorrhea in the United States. Dual therapy with ceftriaxone and azithromycin should be administered together on the same day, preferably simultaneously, and under direct observation. Pregnant women who are infected with N gonorrhoeae should be treated with the recommended dual therapy. A test-of-cure is not needed for individuals diagnosed with uncomplicated urogenital or rectal gonorrhea who are treated with the recommended or alternative regimens.
2.An unusual case of delayed-type hypersensitivity to ceftriaxone and meropenem.
Dias de Castro E1, Leblanc A2, Sarmento A3, Cernadas JR2. Eur Ann Allergy Clin Immunol. 2015 Nov;47(6):225-7.
Recent studies have demonstrated a low cross-reactivity between β-lactam antibiotics and carbapenems in IgE-mediated reactions. There are no studies on cross-reactivity of meropenem in patients with non-immediate hypersensitivity to cephalosporins. We describe a case of a 13-year-old male, admitted in Neurosurgery with a severe extradural empyema complicating frontal sinusitis, submitted to an emergent bifrontal craniotomy. A generalized maculopapular exanthema, fever and malaise, appeared by the 7th day of meningeal doses of ceftriaxone, clindamycin and vancomycin. Those were replaced by meropenem, with posterior worsening of the reaction and mucosal involvement. A new scheme with amikacin, metronidazole and linezolid was done with improvement. Skin prick, intradermal and patch tests to penicillins, ceftriaxone and meropenem were negative. Lymphocyte transformation test was positive to ceftriaxone and negative to meropenem.Non-immediate T cell mechanism seems to be involved.
3.Lyme Carditis in the Fast Lane: From Alternating Bundle Branch Block to Asystole in 12 Hours.
Khalil S, Padala SK, Hui CM, Steckman DA, Sidhu MS, Torosoff MT. Conn Med. 2015 Oct;79(9):517-20.
Lyme borreliosis is a multisystem infectious disease with well-known cardiac involvement, including potential carditis as well as conduction abnormalities. We report a case of Lyme disease in a previously healthy 24-year-old male presenting with alternating right- and left-bundle branch block, indicating infra-Hisian atrioventricular (infra-His) block with an accelerated fascicular escape rhythm. Inless than 12 hours, the conduction abnormalities progressed to asystole requiring the urgent placement of a temporary transvenous pacemaker. Subsequently, with appropriate antibiotic treatment, the patient's conduction abnormalities resolved in a week without the need for a permanent pacemaker.
4.Experimental closure of gunshot wounds by fibrin glue with antibiotics in pigs.
Djenić N, Višnjić M, Dragović S, Bojanić V, Bojanić Z, Djurdjević D, Djindjić B, Kostov M. Vojnosanit Pregl. 2015 Sep;72(9):785-93.
BACKGROUND/AIM: Gunshot wounds caused by the automatic rifle M70AB2 (AK-47) 7.62 mm, after the primary surgical management, were closed with delayed primary suture during the next four to seven days. This period coincides with the fibroblastic phase of wound healing. Fibrin glue is used as a local hemostatic and as a matrix for the local dosed release of antibiotics. Antibiotics addition to fibrin glue resulted in continuous diffusion into the surrounding next 4 to 7 days. The aim of this study was to create the preconditions for gunshot wounds closing without complications by the application of fibrin glue with antibiotics 24 h after primary surgical treatment.
Recommended Products
| BBF-05862 | Epirubicin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
